HBM Healthcare Investments
Venture Capital
Active
Zug, Switzerland
243
44M
127
10.57
31
0.47
58
- Stages of investment
- Areas of investment
Summary
The main office of represented VC is situated in the Zug. The company was established in Europe in Switzerland.
Among the most popular portfolio startups of the fund, we may highlight ARMO BioSciences, Harmony Biosciences, Vivoryon Therapeutics. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Medical, Medical Device. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. The fund has exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager.
Besides them, we counted 4 critical employees of this fund in our database.
The top activity for fund was in 2007. Despite it in 2019 the fund had an activity. The typical startup value when the investment from HBM Healthcare Investments AG is 100-500 millions dollars. Speaking about the real fund results, this VC is 6 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this HBM Healthcare Investments AG performs on 3 percentage points less the average number of lead investments. The fund is generally included in 2-6 deals every year. The increased amount of exits for fund were in 2018. Deals in the range of 10 - 50 millions dollars are the general things for fund.
The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the HBM Healthcare Investments AG, startups are often financed by OrbiMed, Kleiner Perkins, Novo Holdings. The meaningful sponsors for the fund in investment in the same round are OUP (Osage University Partners), Novartis Venture Fund, Venrock. In the next rounds fund is usually obtained by SV Health Investors, Alta Partners, Maverick Ventures.
Investor highlights
- Industry focus
- Stage focus
- Geo focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 243
- Lead investments
- 31
- Exits
- 58
- Rounds per year
- 10.57
- Follow on index
- 0.47
- Investments by industry
- Biotechnology (180)
- Health Care (155)
- Medical (102)
- Pharmaceutical (69)
- Therapeutics (56) Show 38 more
- Investments by region
-
- United States (149)
- China (9)
- Switzerland (17)
- Denmark (4)
- Germany (19) Show 13 more
- Peak activity year
- 2020
- Number of Unicorns
- 3
- Number of Decacorns
- 3
- Number of Minotaurs
- 4
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 13
- Avg. valuation at time of investment
- 79M
- Group Appearance index
- 0.75
- Avg. company exit year
- 10
- Avg. multiplicator
- 2.08
- Strategy success index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Karius | 02 May 2024 | Biotechnology, Information Technology, Genetics, Life Science | Late Stage Venture | 100M | United States, California, Redwood City |
Sphingotec GmbH | 19 Jul 2022 | Biotechnology | Early Stage Venture | Brandenburg, Hohen Neuendorf, Germany |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.